In March 2026, researchers from the University of Southern Denmark (SDU) and Odense University Hospital published a discovery that could transform how we screen for and understand colorectal cancer: a previously unknown virus, hidden inside one of the most common bacteria in the human gut, appears with significantly higher frequency in patients diagnosed with this form of cancer.
The virus — a type of bacteriophage, meaning a virus that infects bacteria rather than human cells — was found within Bacteroides fragilis, a bacterium that inhabits the intestines of virtually all healthy people. The crucial difference is that colorectal cancer patients were approximately twice as likely to carry this specific virus compared to people without the disease.
The study, published in the journal Communications Medicine, involved institutions in Denmark and Australia and represents a significant advance in understanding the relationship between the gut microbiome and cancer development. With more than 55,000 Americans expected to die of colorectal cancer this year alone, any advancement in early screening has the potential to save thousands of lives.
What Happened
To understand the importance of this discovery, one must first grasp what bacteriophages are and why they are so difficult to detect.
Bacteriophages — or simply "phages" — are viruses that exclusively infect bacteria. They are, in fact, the most abundant biological entities on the planet, outnumbering all other forms of life combined. Trillions of them inhabit the human body, especially the gastrointestinal tract, where they coexist with the bacteria that make up our microbiome.
What makes the phage discovered by the Danish team special is that it was integrated into the genome of Bacteroides fragilis — literally hidden within the host bacterium's DNA. This type of phage, called a prophage, can remain dormant for generations, silently replicating alongside the bacterium without causing apparent effects. Under certain conditions, however, the prophage can activate, produce new viral particles, and potentially alter the behavior of the host bacterium.
The research team used advanced metagenomics techniques — the analysis of total genetic material present in biological samples — to identify the virus. Traditional microbiology methods, which depend on culturing organisms in the laboratory, would have failed to detect it because the phage does not manifest visibly when integrated into the bacterial genome.
The discovery was made possible through computational analysis of thousands of gut microbiome samples, systematically comparing bacterial genomes from colorectal cancer patients and healthy individuals. The pattern emerged with statistical clarity: the presence of the specific phage within Bacteroides fragilis was consistently more frequent in cancer patients.
The study published in Communications Medicine analyzed gut microbiome samples from hundreds of colorectal cancer patients and healthy individuals matched by age, sex, and other demographic factors. The results were consistent and statistically significant.
Colorectal cancer patients were approximately twice as likely to carry the specific phage within their Bacteroides fragilis populations compared to the healthy control group. This association persisted even after adjustments for confounding factors such as diet, antibiotic use, body mass index, and family history of cancer.
It is important to emphasize that association is not the same as causation. The study demonstrates that the virus is more frequent in cancer patients, but does not prove that the virus causes cancer. There are several possible explanations for the association: the virus may directly contribute to cancer development; the tumor environment may favor virus activation; or both may be consequences of a third, as yet unidentified factor.
The researchers are cautious in their conclusions, emphasizing that longitudinal studies — which follow individuals over time to see who develops cancer — will be necessary to establish whether the relationship is causal. However, even as an association biomarker, the phage has significant clinical potential.
The phage discovery in Bacteroides fragilis fits into a growing body of evidence connecting the gut microbiome to the development of various types of cancer, especially colorectal.
Over the past two decades, researchers have identified several bacteria associated with colorectal cancer, including Fusobacterium nucleatum, Peptostreptococcus anaerobius, and certain strains of Escherichia coli. Each of these bacteria appears to contribute to cancer development through different mechanisms — toxin production, inflammation promotion, direct DNA damage to intestinal cells, or immune system modulation.
What the phage discovery adds is a new dimension: it is not just the bacteria that matter, but also the viruses living inside them. This insight enormously expands the universe of microbial factors that may influence cancer risk and suggests that analyses focused solely on bacteria may be missing an important part of the picture.
The concept of the virome — the complete set of viruses present in an organism — is gaining increasing attention in medical research. Like the bacterial microbiome, the gut virome is vast, diverse, and still largely unexplored. The discovery of the phage associated with colorectal cancer is one of the first concrete examples of how viruses within bacteria can have direct impact on human health.
Context and Background
Bacteroides fragilis is one of the most studied and most common bacteria in the human gut. It is part of the normal microbiome of virtually all people and, in most cases, performs beneficial functions — helping digest complex carbohydrates, producing vitamins, and contributing to immune system maturation.
However, certain strains of B. fragilis were already known to produce a toxin called fragilysin (or BFT — Bacteroides fragilis toxin), which can damage the intestinal lining and promote chronic inflammation. Previous studies had already associated these toxigenic strains with an increased risk of colorectal cancer, but the relationship had never been fully clarified.
The phage discovery adds a new layer of complexity to this story. The researchers' hypothesis is that the virus may alter the bacterium's behavior in ways that promote cancer development — whether by stimulating toxin production, modifying the local immune response, or altering bacterial metabolism in ways that create an environment favorable to tumor growth.
The crucial point is that Bacteroides fragilis itself is not the problem — it is present in healthy and sick people equally. What differentiates the two groups is the presence of the virus inside the bacterium. This distinction is fundamental because it suggests that the phage may be a more specific biomarker for colorectal cancer risk than the simple presence of the bacterium.
The study was the result of an international collaboration involving institutions in Denmark and Australia. The core team was based at the University of Southern Denmark (SDU) and Odense University Hospital, with contributions from Australian researchers who provided additional samples and expertise in metagenomic analysis.
This international collaboration was essential for several reasons. First, it allowed access to a larger and more diverse number of samples, increasing the study's statistical power. Second, replication of results in populations from different continents strengthens the evidence that the association between the phage and colorectal cancer is not an artifact of a specific population but a potentially universal phenomenon.
The Danish researchers have already announced plans for follow-up studies that will include longitudinal analyses — tracking healthy individuals who carry the phage over several years to determine whether they develop colorectal cancer more frequently. These studies will be crucial for establishing causality and evaluating the phage's potential as a clinical screening tool.
Impact on the Population
| Aspect | Previous Situation | Current Situation | Impact |
|---|---|---|---|
| Scale | Limited | Global | High |
| Duration | Short-term | Medium/long-term | Significant |
| Reach | Regional | International | Broad |
Colorectal cancer is the third most common type of cancer worldwide and the second leading cause of cancer death. Despite being highly treatable when detected early, many cases are diagnosed at advanced stages because current screening methods have significant limitations.
Colonoscopy, considered the gold standard, is invasive, uncomfortable, and requires bowel preparation that many patients avoid. Fecal occult blood tests are less invasive but have significant rates of false positives and false negatives. Stool DNA tests, like Cologuard, are more accurate but expensive and not widely available in many countries.
The phage discovery opens the possibility of a new type of screening test: detection of the specific virus in stool or blood samples. If future studies confirm that the phage's presence precedes cancer development (and is not merely a consequence of it), this test could identify individuals at elevated risk years before the appearance of symptoms or tumors detectable by colonoscopy.
A test based on phage detection would have several advantages: it would be non-invasive (based on stool samples), relatively inexpensive (using PCR techniques already widely available), and potentially more specific than current tests (because the phage appears to be a more precise marker than other microbial indicators).
The urgency of this research cannot be overstated when viewed against the backdrop of colorectal cancer's devastating toll. More than 55,000 Americans are expected to die of colorectal cancer this year alone, making it the second leading cause of cancer death in the United States. Globally, colorectal cancer claims approximately 900,000 lives annually.
What makes these statistics particularly tragic is that colorectal cancer is one of the most preventable and treatable cancers when caught early. Five-year survival rates exceed 90% for localized disease but plummet to around 15% for distant metastatic disease. The difference between life and death often comes down to early detection — and current screening methods leave significant gaps.
The rising incidence of colorectal cancer in younger adults — those under 50 — adds another dimension of urgency. Over the past two decades, colorectal cancer rates in adults aged 20-49 have increased by approximately 50% in many developed countries. The reasons for this trend are not fully understood, but changes in diet, microbiome composition, and environmental exposures are suspected contributors. A screening tool based on the newly discovered phage could be particularly valuable for this younger population, who are not yet covered by standard screening guidelines.
What the Key Players Are Saying
Next Steps
The discovery is promising, but it is essential to maintain realistic expectations about the path between a scientific discovery and a clinical application. Several steps are necessary before this research translates into direct benefits for patients.
First, the association needs to be confirmed in larger and more diverse studies, including populations of different ethnicities, diets, and lifestyles. Second, longitudinal studies need to determine whether the phage's presence precedes cancer development. Third, the biological mechanisms by which the phage may contribute to cancer need to be elucidated in laboratory studies. Fourth, if the phage is confirmed as a useful biomarker, diagnostic tests need to be developed, validated, and approved by regulatory agencies.
This process typically takes 5 to 15 years, depending on complexity and intermediate results. However, the urgency of the problem — tens of thousands of annual deaths from colorectal cancer that could be prevented with more effective screening — may accelerate the process if initial results continue to be promising.
Meanwhile, the discovery already has immediate scientific value: it expands our understanding of the complex relationship between viruses, bacteria, and cancer, and opens new lines of investigation that may lead to additional discoveries about the role of the virome in human health.
Closing
Meanwhile, the discovery already has immediate scientific value: it expands our understanding of the complex relationship between viruses, bacteria, and cancer, and opens new lines of investigation that may lead to additional discoveries about the role of the virome in human health.
Sources and References
- SciTechDaily: Scientists Discover Hidden Virus Linked to Colorectal Cancer
- Science Alert: Hidden Virus Found in Gut Bacteria Is Linked to Colorectal Cancer
- SDU: Nyopdaget virus kobles til tarmkræft
- Gavi: Virus Hiding Inside Bacteria May Help Explain Colorectal Cancer
- Independent: Colorectal Cancer Gut Virus Detection Denmark
